August 18, 2011
Angiogenesis Research Pioneer Robert S. Kerbel, Ph.D. to be Keynote Speaker at the Angiogenesis Foundation’s 2011 M. Judah Folkman Conference: New Frontiers in Therapeutic Development
CAMBRIDGE, Mass., Aug. 18, 2011 /PRNewswire/ -- Leading angiogenesis and cancer researcher Dr. Robert S. Kerbel of the University of Toronto will deliver the Future of Medicine Keynote Address at the Angiogenesis Foundation's 9th International M. Judah Folkman Conference -- New Frontiers in Therapeutic Development. The conference will take place on October 29-30, 2011 in Cambridge, MA, and attracts key opinion leaders from academia, industry and government to discuss the latest scientific and clinical findings on antiangiogenic cancer therapies.
Dr. Kerbel is one of the world's leading authorities on tumor angiogenesis. His research group at the University of Toronto is looking at innovative new ways to use both conventional chemotherapy and antiangiogenic agents to treat cancer. Dr. Kerbel's keynote address, titled "Metronomic Antiangiogenic Chemotherapy: Past, Present and Future," will present his latest findings on antiangiogenic metronomic cancer therapy.Registration for the conference is now open. To review the topic and speaker agenda visit http://www.angio.org/programs-cp-aa11.php.
This year's conference will include presentations by leaders from Harvard Medical School, the U.S. National Cancer Institute, University of Texas MD Anderson, Memorial Sloan Kettering Cancer Center, Stanford University, Queen's University Belfast, Johannes Gutenberg University Mainz, IRCCS Multimedica Milan, and other top research institutions.
Topics to be covered at this year's meeting include:
- Anti-VEGF therapy resistance and antiangiogenic escape
- VEGF-independent tumor angiogenesis
- Glioblastoma vasculature and stem cells
- Novel therapy biomarker
- Influence of diet on angiogenic signaling pathways
As the world's leading non-profit organization dedicated to advancing the field of angiogenesis research, the Angiogenesis Foundation takes a multidisciplinary approach to its annual conference, bringing together experts and key stakeholders from basic research, life sciences industry, clinical investigation, and government to foster new collaborations and exchanges between faculty and attendees.
Due to limited space, early registration is encouraged. For additional information please contact, Michelle Sylvanowicz at (617) 401-2779.
SOURCE The Angiogenesis Foundation